Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2003

Rossi S, Loda M. The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes. Breast Cancer Res. 2003;5(1):16-22.

Gu L, Zheng H, Murray SA, Ying H, Xiao Z-. Deregulation of Cdc2 kinase induces caspase-3 activation and apoptosis. Biochem Biophys Res Commun. 2003;302(2):384-91.

Ding R, Li B, Muthukumar T, Dadhania D, Medeiros M, Hartono C, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation. 2003;75(8):1307-12.

Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919-27.

Huang XG, Yee BK, Nag S, Chan ST, Tang F. Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235. Exp Neurol. 2003;183(2):673-81.

Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep. 2003;4(3):307-12.

Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest. 2003;112(2):170-80.

Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G, et al. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia. 2003;17(11):2238-40.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9.

Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol. 2003;31(8):702-7.